NAGIOS: RODERIC FUNCIONANDO

Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials

Repositori DSpace/Manakin

IMPORTANT: Aquest repositori està en una versió antiga des del 3/12/2023. La nova instal.lació está en https://roderic.uv.es/

Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials

dc.contributor.author	Piñana, José Luis	es_ES
dc.contributor.author	Martino, Rodrigo	es_ES
dc.contributor.author	Gayoso, Jorge	es_ES
dc.contributor.author	Sureda, Anna	es_ES
dc.contributor.author	Serna, Javier de la	es_ES
dc.contributor.author	Díez-Martín, Jose Luis	es_ES
dc.contributor.author	Vázquez, Lourdes	es_ES
dc.contributor.author	Arranz, Reyes	es_ES
dc.contributor.author	Tomás, José Francisco	es_ES
dc.contributor.author	Sampol Mayol, Antonia	es_ES
dc.contributor.author	Solano Vercet, Carlos	es_ES
dc.contributor.author	Delgado, Julio	es_ES
dc.contributor.author	Sierra, Jorge	es_ES
dc.contributor.author	Caballero, Dolores	es_ES
dc.date.accessioned	2015-06-29T10:34:10Z
dc.date.available	2015-06-29T10:34:10Z
dc.date.issued	2010	es_ES
dc.identifier.citation	Haematologica Vol. 95 Issue 7: pp. 1176-1182	es_ES
dc.identifier.uri	http://hdl.handle.net/10550/44807
dc.description.abstract	BackgroundAllogeneic hematopoietic stem cell transplantation is an effective treatment for patients with poor risk lymphoma, at least in part because of the graft-versus-lymphoma effect. Over the past decade, reduced intensity conditioning regimens have been shown to offer results similar to those of conventional high-dose conditioning regimens but with lower toxicity early after transplantation, especially in patients with chemosensitive disease at transplant.Design and MethodsThe aim of this study was to analyze the long-term outcome of patients with follicular lymphoma who received an HLA identical sibling allogeneic stem cell transplant with a reduced intensity conditioning regimen within prospective trials. The prospective multicenter studies considered included 37 patients with follicular lymphoma who underwent allogeneic stem cell transplantation between 1998 and 2007 with a fludarabine plus melphalan-based reduced intensity conditioning regimen.ResultsThe median age of the patients was 50 years (range, 34–62 years) and the median follow-up was 52 months (range, 0.6 to 113 months). Most patients (77%) had stage III-IV at diagnosis, and patients had received a median of three lines of therapy before the reduced intensity conditioning allogeneic stem cell transplantation. At the time of transplantation, 14 patients were in complete remission, 16 in partial remission and 7 had refractory or progressive disease after salvage chemotherapy. The 4-year overall survival rates for patients in complete remission, partial remission, or with refractory or progressive disease were 71%, 48% and 29%, respectively (P=0.09), whereas the 4-year cumulative incidences of non-relapse mortality were 26% (95% CI, 11–61), 33% (95% CI, 16–68) and 71% (95% CI, 44–100), respectively. The incidence of relapse for the whole group was only 8% (95% CI, 2–23).ConclusionsWe conclude that this strategy of reduced intensity conditioning allogeneic stem cell transplantation may be associated with significant non-relapse mortality in heavily pre-treated patients with follicular lymphoma, but a remarkably low relapse rate. Long-term survival is likely in patients without progressive or refractory disease at the time of transplantation.	es_ES
dc.subject	follicular lymphoma	es_ES
dc.subject	reduced intensity conditioning	es_ES
dc.subject	HLA identical sibling donor	es_ES
dc.subject	allogeneic stem cell transplantation	es_ES
dc.subject	graft-versus-host disease	es_ES
dc.title	Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials	es_ES
dc.type	journal article	es_ES
dc.identifier.doi	10.3324/haematol.2009.017608	es_ES
dc.identifier.idgrec	066494	es_ES